MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.gastrohep.2024.502197

Медицинская библиотека · Gastroenterologia y hepatologia · 2024

Efficacy and safety of biological treatment for inflammatory bowel disease in elderly patients: Results from a GETECCU cohort.

Suárez Ferrer Cristina, Mesonero Gismero Francisco, Caballol Berta, Ballester Maria Pilar, Bastón Rey Iria, Castaño García Andrés, Miranda Bautista Jose, Saiz Chumillas Rosa, Benitez Jose Manuel, Sanchez-Delgado Laura, López-García Alicia, Rubin de Celix Cristina, Alonso Abreu Inmaculada, Melcarne Luigi, Plaza Santos Rocío, Marques-Camí Miquel, Caballero Mateos Antonio, Gómez Díez César, Calafat Margalida, Galan Horacio Alonso, Vega Vilaamil Pablo, Castro Senosiain Beatriz, Guerro Moya Andrea, Rodriguez Diaz Carmen Yolanda, Spicakova Katerina, Manceñido Marcos Noemi, Molina Gema, de Castro Parga Luisa, Rodriguez Angulo Andres, Cuevas Del Campo Lidia, Rodriguez Grau Maria Del Carmen, Ramirez Fernando, Gomez Pastrana Barbara, Gonzalez Partida Irene, Botella Mateu Belen, Peña Gonzalez Elena, Iyo Eduardo, Elosua Gonzalez Alfonso, Sainz Arnau Empar, Hernandez Villalba Luis, Perez Galindo Pablo, Torrealba Medina Leyanira, Monsalve Alonso Sara, Olmos Perez Jose Antonio, Dueñas Sadornil Carmen, Garcia Ramirez Laura, Martín-Arranz María Dolores, López Sanroman Antonio, Fernández Agnès, Merino Murgui Victor, Calviño Suárez Cristina, Flórez-Diez Pablo, Lobato Matilla María Elena, Sicilia Beatriz, Soto Escribano Pilar, Maroto Martin Carlos, Mañosa Míriam, Barreiro-De Acosta Manuel, On belhaf of Young group of GETECCU

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

INTRODUCTION

Biological therapies used for the treatment of inflammatory bowel disease (IBD) have shown to be effective and safe, although these results were obtained from studies involving mostly a young population, who are generally included in clinical trials. The aim of our study was to determine the efficacy and safety of the different biological treatments in the elderly population.

METHODS

Multicenter study was carried out in the GETECCU group. Patients diagnosed with IBD and aged over 65 years at the time of initiating biological therapy (infliximab, adalimumab, golimumab, ustekinumab or vedolizumab) were retrospectively included. Among the patients included, clinical response was assessed after drug induction (12 weeks of treatment) and at 52 weeks. Patients' colonoscopy data in week 52 were assessment, where available. Regarding complications, development of oncological events during follow-up and infectious processes occurring during biological treatment were collected (excluding bowel infection by cytomegalovirus).

RESULTS

A total of 1090 patients were included. After induction, at approximately 12-14 weeks of treatment, 419 patients (39.6%) were in clinical remission, 502 patients (47.4%) had responded without remission and 137 patients (12.9%) had no response. At 52 weeks of treatment 442 patients (57.1%) had achieved clinical remission, 249 patients had responded without remission (32.2%) and 53 patients had no response to the treatment (6.8%). Before 52 weeks, 129 patients (14.8%) had discontinued treatment due to inefficacy, this being significantly higher (p<0.0001) for Golimumab - 9 patients (37.5%) - compared to the other biological treatments analyzed. With respect to tumor development, an oncological event was observed in 74 patients (6.9%): 30 patients (8%) on infliximab, 23 (7.14%) on adalimumab, 3 (11.1%) on golimumab, 10 (6.4%) on ustekinumab, and 8 (3.8%) on vedolizumab. The incidence was significantly lower (p=0.04) for the vedolizumab group compared to other treatments. As regards infections, these occurred in 160 patients during treatment (14.9%), with no differences between the different biologicals used (p=0.61): 61 patients (19.4%) on infliximab, 39 (12.5%) on adalimumab, 5 (17.8%) on golimumab, 22 (14.1%) on ustekinumab, and 34 (16.5%) on vedolizumab.

CONCLUSIONS

Biological drug therapies have response rates in elderly patients similar to those described in the general population, Golimumab was the drug that was discontinued most frequently due to inefficacy. In our experience, tumor development was more frequent in patients who used anti-TNF therapies compared to other targets, although its incidence was generally low and that this is in line with younger patients based on previous literature.

Для цитирования: Suárez Ferrer Cristina, Mesonero Gismero Francisco, Caballol Berta, Ballester Maria Pilar, Bastón Rey Iria, Castaño García Andrés, Miranda Bautista Jose, Saiz Chumillas Rosa, Benitez Jose Manuel, Sanchez-Delgado Laura, López-García Alicia, Rubin de Celix Cristina, Alonso Abreu Inmaculada, Melcarne Luigi, Plaza Santos Rocío, Marques-Camí Miquel, Caballero Mateos Antonio, Gómez Díez César, Calafat Margalida, Galan Horacio Alonso, Vega Vilaamil Pablo, Castro Senosiain Beatriz, Guerro Moya Andrea, Rodriguez Diaz Carmen Yolanda, Spicakova Katerina, Manceñido Marcos Noemi, Molina Gema, de Castro Parga Luisa, Rodriguez Angulo Andres, Cuevas Del Campo Lidia, Rodriguez Grau Maria Del Carmen, Ramirez Fernando, Gomez Pastrana Barbara, Gonzalez Partida Irene, Botella Mateu Belen, Peña Gonzalez Elena, Iyo Eduardo, Elosua Gonzalez Alfonso, Sainz Arnau Empar, Hernandez Villalba Luis, Perez Galindo Pablo, Torrealba Medina Leyanira, Monsalve Alonso Sara, Olmos Perez Jose Antonio, Dueñas Sadornil Carmen, Garcia Ramirez Laura, Martín-Arranz María Dolores, López Sanroman Antonio, Fernández Agnès, Merino Murgui Victor, Calviño Suárez Cristina, Flórez-Diez Pablo, Lobato Matilla María Elena, Sicilia Beatriz, Soto Escribano Pilar, Maroto Martin Carlos, Mañosa Míriam, Barreiro-De Acosta Manuel, On belhaf of Young group of GETECCU. Efficacy and safety of biological treatment for inflammatory bowel disease in elderly patients: Results from a GETECCU cohort.. Gastroenterologia y hepatologia. 2024. DOI: 10.1016/j.gastrohep.2024.502197.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.